Daily Bulletin

Men's Weekly

.

  • Written by PR Newswire Asia - Daily Bulletin Au RSS
Metavention Announces Initiation of Groundbreaking Multi-Organ Denervation Study

MINNEAPOLIS, May 4, 2021 /PRNewswire/ -- Metavention, Inc. announces the initiation of the MODUS Study (ACTRN12620000412932), to treat patients with both type 2 diabetes and hypertension using a catheter-based, minimally invasive approach.

The first procedures in this study were successfully completed at The Alfred Hospital in Melbourne, Australia by Dr. Gerard Goh. The study procedures are performed with a novel integrated RF denervation system (iRF Denervation System, Metavention Inc.). Dr. Goh commented, "On behalf of the entire team at The Alfred, we're excited to be part of this groundbreaking study of the Metavention iRF Denervation System in patients with cardiometabolic syndrome. The iRF denervation procedure has the potential to significantly alter how we look at treating patients suffering from cardiometabolic syndrome."

The MODUS Study is a prospective, randomized, 3-arm, multi-centre, single-blind trial to evaluate the safety and performance of multi-organ sympathetic denervation in patients with type 2 diabetes and hypertension.  Sympathetic nerve overactivity to key metabolic organs, such as the liver and kidneys, is associated with elevated blood pressure and uncontrolled glucose.  Multi-organ denervation is intended to inhibit this overactivity, and with a single treatment, improve control of hypertension and glucose. The MODUS Study design uses randomization to place subjects into one of three procedure options, renal denervation (kidney), hepatic denervation (liver), or multi-organ denervation (both kidneys and the liver).

Patients are currently being recruited for the MODUS Study in Brisbane, Melbourne, and Perth. For more information, please visit www.modusstudy-au.com.

About Cardiometabolic Syndrome

Cardiometabolic Syndrome (CMS) is a clustering of disorders mainly characterized by hypertension, type 2 diabetes, high cholesterol, and a large waist circumference. About 25% of the world's adults suffer from CMS, as it is considered to be the primary driver behind the ongoing epidemic of cardiovascular disease in the world.  Patients with CMS are at a significantly higher risk of heart disease, diabetes, and stroke.

About Metavention Inc.

Developer of the iRF Denervation System, Metavention, Inc. is a privately held medical device company headquartered in Minneapolis, Minnesota. The iRF denervation procedure is intended to be a single treatment option to improve glucose and blood pressure control for patients with type 2 diabetes and hypertension.

CAUTION - The iRF Denervation System is an investigational device and is not approved for commercial use in any geography.

Related Linkswww.metavention.com

Logo - https://mma.prnasia.com/media2/1501262/Metavention_Logo.jpg?p=medium600

 

Authors: PR Newswire Asia - Daily Bulletin Au RSS

Read more https://www.prnasia.com/story/archive/3362490_EN62490_0

Business News

Hydrogen Pipe Infrastructure: A Guide to Future Networks

As Australia moves towards a cleaner energy future, hydrogen is emerging as a key player. But how do we get this promising energy source from production facilities to where it's needed? The answer l...

Daily Bulletin - avatar Daily Bulletin

Wang Chuanfu Attends BYD Harmony’s 100th Overseas Store Opening

Dignitaries inaugurate the new store On July 12, 2025, Melbourne, the vibrant pearl of the southern hemisphere, Chairman and President of BYD Co., Ltd. Mr. Wang Chuanfu inaugurated and awarded the ...

Daily Bulletin - avatar Daily Bulletin

Strategic Global Expansion Moves to Overcome the Growth Challenges

Photo by Gabrielle Henderson on Unsplash Australia's startup ecosystem is having a moment in the sun. Out of 1,257 unicorns globally, eight hail from Australia. Yet, trade and economic policy uncerta...

Daily Bulletin - avatar Daily Bulletin

LayBy Deals